News from Canary Rx Website
Share Exchange 25.5 mil of CBDY in exchange for Visava 100% interest in Canary Rx Inc.
Before Merger March 31, 2018 25,960,339 Total Shares Outstanding
Capital Structure / Conversions
The company has 20 billion shares authorized but went through a reverse stock split and cleaned up the corporation in 2016 and shrunk the share count down to 35,645 shares. As of March 31, 2018, the company currently has 25,960,339 shares issued and outstanding. Of that 17,872,812 is owned by CEO Rubin Schindermann and Alexander Starr which represents 68% of the outstanding shares. This leaves 8,087,527 shares in the potential float. At the end of 2017 the number of shares converted was 1,922,094 and 96,094 for advisory services. In 2018 5,156,932 shares were converted for $21,518 representing a conversion price of $.00417. This means that 3-4 people have concentrated control of 7,175,120 shares of the float and that 912,407 shares represent the small investors float. Subsequent events show an additional 500,000 shares were issued to a consultant in April 2018 which could mean that some sort of reverse merger is coming into this company.